Fosamax and Osteonecrosis of the Jaw: Scientific Evidence and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Risk Awareness

The legacy domain of general health and science information has long provided foundational knowledge on a wide range of medical topics, including bone health and medication safety. Within this broad context, public awareness of adverse drug reactions has grown, particularly regarding bisphosphonate therapies used for osteoporosis. Fosamax, a commonly prescribed bisphosphonate, has been associated with a rare but serious condition: osteonecrosis of the jaw (ONJ). This condition involves bone death in the jaw, often following dental procedures, and has prompted scrutiny of the drug’s risk profile. Transitioning from this general health perspective to a more focused concern, the occupational exposure dimension emerges. In mass production settings, workers may encounter Fosamax or its active ingredients during manufacturing, packaging, or quality control processes. Inhalation of dust or dermal contact with the compound could pose risks distinct from those of therapeutic use. The scientific evidence linking Fosamax to ONJ in patients raises questions about whether similar mechanisms might apply to workers with chronic, low-level exposure. This pivot from patient-centered health information to occupational safety considerations underscores the need for targeted risk assessment in industrial environments, where exposure routes and durations differ markedly from clinical scenarios.

Mechanisms Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation typically involves pain, swelling, infection, and exposed bone that fails to heal after dental procedures. Diagnosis relies on clinical examination and imaging, with exclusion of metastatic disease. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to local infections or trauma, such as tooth extraction. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided comprehensive information to help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies in estrogen-deficient rats treated with alendronate have examined effects on jawbone properties, including mechanical stability of teeth in the alveolar socket and tissue mineral density distribution (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that bisphosphonate treatment alters jawbone matrix properties, potentially predisposing to ONJ.

Risk Factors and Clinical Considerations

Risk factors for developing ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under warnings and precautions. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it can occur spontaneously or be associated with dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping, though a subset had recurrence when rechallenged (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, its incidence in clinical trials was low and not significantly different from placebo, which may affect the perception of risk.

Causation and Temporal Considerations

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The timeline between exposure and documented harm can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ is also known to occur spontaneously and is associated with other risk factors, making it challenging to attribute causation solely to Fosamax. The label acknowledges that ONJ can occur spontaneously and is generally associated with dental procedures or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients who develop ONJ while on Fosamax, the drug's discontinuation may lead to symptom relief, but recurrence can occur if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk-benefit assessment should consider the patient's underlying condition, such as osteoporosis, and the availability of alternative treatments. In summary, scientific evidence supports a causal association between Fosamax and osteonecrosis of the jaw, with mechanistic pathways involving suppressed bone remodeling and altered jawbone properties. The prescribing information includes warnings about this risk, but the low incidence in clinical trials and the presence of other risk factors complicate causation determinations. Patients and healthcare providers should be aware of the timeline of symptom onset and the potential for risk reduction through dental evaluation and, if appropriate, drug discontinuation before invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption. Scientific evidence shows that bisphosphonates can accumulate in the jawbone, suppress remodeling, and impair repair of microdamage, leading to ONJ. Animal studies have demonstrated altered jawbone properties (https://pubmed.ncbi.nlm.nih.gov/40345077/). The FDA label includes warnings about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Longer duration of bisphosphonate use may increase risk.

How is causation between Fosamax and ONJ determined?

Causation requires a temporal relationship between Fosamax exposure and ONJ onset, which can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ can occur spontaneously and has other risk factors, making causation complex. Discontinuation may lead to relief, but recurrence can occur upon rechallenge.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.